8legs: Cbdmd, inc.

#1 out of 1

cbdMD Signs New Executive Employment Agreement

cbdMD’s CEO and CFO signed an Executive Employment Agreement with base salary and a restricted stock award contingent on shareholder approval.
The board approved a 2025 Equity Compensation Plan to replace the expired 2015 plan, pending shareholder approval in 2026.
Analysts flag negative earnings and cash flow, contributing to a Sell rating for CBDMD stock (YCBD).
TipRanks’ Spark labels YCBD as Underperform due to weak momentum and negative valuation signals.
cbdMD operates in the wellness sector, offering tinctures, gummies, topicals, and bath bombs.
Trading data and market context come from Barchart Solutions with standard disclosures.
The article features syndicated content with disclosures and a note on content review.
George TipRanks data is referenced for stock analysis and price targets on CBDMD.
The article notes the 2026 shareholder meeting as the venue for plan approvals.
The piece includes a disclaimer about syndicated content and third-party materials.

Vote 0